News & Updates
Filter by Specialty:
Arginine depletion plus chemo ups survival in rare lung cancer
In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.
Arginine depletion plus chemo ups survival in rare lung cancer
31 May 2024
Thyroid cancer patients with a history of breast cancer enjoy survival benefits
A history of breast cancer (BC) appears protective against mortality in patients with thyroid cancer (TC), suggests a study. This benefit is most pronounced with papillary TC (PTC) in patients who had TC first before BC (TC-1st patients), especially in those with a history of ER-positive BC.
Thyroid cancer patients with a history of breast cancer enjoy survival benefits
30 May 2024
MAURIS interim safety and efficacy results in “real-world” ES-SCLC patients similar to IMpower133
Interim results of the Italian, multicentre, open-label, phase IIIb MAURIS trial in “real-world” patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) show similar safety and efficacy to those achieved by atezolizumab plus carboplatin and etoposide in the pivotal, phase I/III IMpower133 trial.
